

List of reference substances of other pharmacopoeias found to be suitable for use according to *The International Pharmacopoeia*.

Name of the reference substance and its intended use according to <i>The International Pharmacopoeia</i> (in brackets)	Name of the reference substance found suitable for the indicated intended use, batch number and issuing pharmacopoeia
4-<i>epi</i>-Anhydrotetracycline hydrochloride (for use in the test for related substances according to the monograph on Tetracycline hydrochloride)	4-Epianhydrotetracycline hydrochloride CRS; Batch 7; European Pharmacopoeia
4-<i>epi</i>-Tetracycline hydrochloride (for use in the test for related substances according to the monograph on Tetracycline hydrochloride)	4-Epitetracycline hydrochloride CRS; Batch 10; European Pharmacopoeia
Anhydrotetracycline hydrochloride (for use in the test for related substances according to the monograph on Tetracycline hydrochloride)	Anhydrotetracycline hydrochloride CRS, Batch 5, European Pharmacopoeia
Atenolol for system suitability RS (containing atenolol and the impurities B, F, G, I and J) for use in the test for related substances according to the monograph on Atenolol)	Atenolol for system suitability CRS, Batch 3, European Pharmacopoeia
Benzathine benzylpenicillin for peak identification RS (containing the impurities A, B, C, D, E, F, G, H, I, J and K)	Benzathine benzylpenicillin for peak identification CRS; Batch 1; European Pharmacopoeia
Benzathine benzylpenicillin RS	Benzathine benzylpenicillin CRS, Batch 3; European Pharmacopoeia
Ciprofloxacin hydrochloride for peak identification RS (containing ciprofloxacin and the impurities B, C, D and E) (for use in the test for related substances according to the monograph on Ciprofloxacin hydrochloride and Ciprofloxacin tablets)	Ciprofloxacin hydrochloride for peak identification CRS; Batch 4; European Pharmacopoeia
Clofazimine for system suitability RS (containing clofazimine and impurity B)	Clofazimine for system suitability CRS, Batch 1; European Pharmacopoeia
Ethambutol for system suitability RS (containing ethambutol and impurity B)	Ethambutol for system suitability CRS, Batch 3; European Pharmacopoeia
Ganciclovir for system suitability RS (containing the impurities A, B, C, D, E and F) (for use in the test for related substances according	Ganciclovir impurity mixture CRS, Batch 2, European Pharmacopoeia

to the monograph on Ganciclovir, Ganciclovir for injection)	
Lamivudine for system suitability 1 (containing lamivudine and impurities A and B) (for use in the test for related substances according to the monograph on Lamivudine, Lamivudine oral solution, Lamivudine tablets and Zidovudine and lamivudine tablets)	Lamivudine for system suitability 1 CRS; Batch 1; European Pharmacopoeia
Lamivudine for system suitability 2 (containing lamivudine and impurity D) (for use in the test for impurity D according to the monograph on Lamivudine)	Lamivudine for system suitability 2 CRS; Batch 3; European Pharmacopoeia
Levofloxacin for system suitability RS (containing levofloxacin and the impurities A, B and G) (for use in the test for related substances according to the monograph on Norethisterone and Norethisterone tablets)	Levofloxacin for system suitability CRS; Batch 2; European Pharmacopoeia
Levonorgestrel for system suitability 1 RS (containing the impurities A, H, K, M, O and S) (for use in the test for related substances according to the monograph on Levonorgestrel)	Levonorgestrel for system suitability 1 CRS; Batch 3; European Pharmacopoeia
Levonorgestrel for system suitability 2 RS (containing the impurities V and W) (for use in the test for related substances according to the monograph on Levonorgestrel)	Levonorgestrel for system suitability 2 CRS; Batch 2; European Pharmacopoeia
Mebendazole for system suitability RS (containing the impurities A, B, C, D, E, F and G) (for use in the test for related substances according to the monograph on Mebendazole, Mebendazole chewable tablets)	Mebendazole for system suitability CRS; Batch1; European Pharmacopoeia
Medroxyprogesterone acetate for system suitability RS (containing medroxyprogesterone acetate and the impurities A, B, C, D, E, G and I) (for use in the test for related substances according to the monograph on Medroxyprogesterone acetate and Medroxyprogesterone injection)	Medroxyprogesterone acetate for system suitability CRS; Batch 2; European Pharmacopoeia
Misoprostol (for use in identity tests by IR and TLC, dissolution test and assays according to the monographs on Misoprostol, Misoprostol dispersion and Misoprostol tablets.	Misoprostol CRS; Batch 4; European Pharmacopoeia
Moxifloxacin for peak identification A RS (containing	Moxifloxacin for peak identification A CRS; Batch 1; European

moxifloxacin and the impurities A, B and E) (for use in the test for related substances according to the monograph on Moxifloxacin HCl)	Pharmacopoeia
Moxifloxacin for peak identification B RS (containing moxifloxacin and the impurity F) (for use in the test for related substances according to the monograph on Moxifloxacin HCl)	Moxifloxacin for peak identification B CRS; Batch 2; European Pharmacopoeia
Moxifloxacin for system suitability RS (containing moxifloxacin and the impurities G) (for use in the test for impurity G according to the monograph on Moxifloxacin HCl)	Moxifloxacin for system suitability CRS; Batch 1; European Pharmacopoeia
Norethisterone for system suitability RS (containing the impurities A, B, C, D, E, F, G and H) (for use in the test for related substances according to the monograph on Norethisterone and Norethisterone tablets)	Norethisterone for system suitability CRS; Batch2; European Pharmacopoeia
Zidovudine for system suitability A RS (containing zidovudine and impurity G)	Zidovudine for system suitability A CRS, Batch 1; European Pharmacopoeia
Zidovudine impurity D	Zidovudine impurity D CRS, Batch 1; European Pharmacopoeia

WHO/HSD/HPS/PSN/2026.2

© World Health Organization 2026

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. List of reference substances of other pharmacopoeias found to be suitable for use according to *The International Pharmacopoeia*. Geneva: World Health Organization; 2026 (WHO/HSD/HPS/PSN/2026.2). Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/).

Cataloguing-in-Publication (CIP) data. CIP data are available at <https://iris.who.int/>.

Sales, rights and licensing. To purchase WHO publications, see <https://www.who.int/publications/book-orders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.